{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:06:33Z","timestamp":1773677193737,"version":"3.50.1"},"reference-count":52,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2013]]},"DOI":"10.3960\/jslrt.53.9","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T23:26:52Z","timestamp":1371770812000},"page":"9-19","source":"Crossref","is-referenced-by-count":21,"title":["The Evaluation of Immunohistochemical Markers and Thymic Cortical Microenvironmental Cells in Distinguishing Thymic Carcinoma from Type B3 Thymoma or Lung Squamous Cell Carcinoma"],"prefix":"10.3960","volume":"53","author":[{"given":"Atsushi","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Fumon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Suster S, Moran CA: Thymoma, atypical thymoma, and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms. Am J Clin Pathol 111:826-833, 1999","DOI":"10.1093\/ajcp\/111.6.826"},{"key":"2","unstructured":"2 World Health Organization Classification of Tumours. Pathology and Genetics of Tumuors of Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, M&uuml;ller-Hermelink HK, Harris CC (eds): 1st ed, Lyon, International Agency for Research on Cancer (IRAC) Press, 2004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Pan CC, Chen PC, Chiang H: KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 202:375-381, 2004","DOI":"10.1002\/path.1514"},{"key":"4","unstructured":"4 Kojika M, Ishii G, Yoshida J, Nishimura M, Hishida T, <I>et al<\/I>.: Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma : diagnostic utility of hypoxic marker GLUT-1, in thymic epithelial neoplasms. Mod Pathol 22:1341-1350, 2009"},{"key":"5","unstructured":"5 Hishima T, Fukayama M, Fujisawa M, Hayashi Y, Arai K, <I>et al<\/I>.: CD5 expression in thymic carcinoma. Am J Pathol 145:268-275, 1994"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Wakimoto T, Tomisaka R, Nishikawa Y, Sato H, Yoshino T, <I>et al<\/I>.: Identification and characterization of human thymic cortical dendritic macrophages that may act as professional scavengers of apoptotic thymocytes. Immunobiology 213:837-847, 2008","DOI":"10.1016\/j.imbio.2008.07.032"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Takahama Y: Journey through the thymus : stromal guides for T-cell development and selection. Nat Rev Immunol 6:127-135, 2006","DOI":"10.1038\/nri1781"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kim CH, Broxmeyer HE: Chemokines : signal lamps for trafficking of T and B cells for development and effector function. J Leukoc Biol 65:6-15, 1999","DOI":"10.1002\/jlb.65.1.6"},{"key":"9","unstructured":"9 Hayashi A, Fumon T, Miki Y, Takahashi K: Useful immunohistochemical and functional markers in distinguishing thymic carcinomas from thymomas and\/or squamous cell carcinomas. J Thoracic Oncol 6 (Suppl 2):S1369-1370, 2011 (<I>Abstract<\/I>)"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Tomaru U, Ishizu A, Murata S, Miyatake Y, Suzuki S, <I>et al<\/I>.: Exclusive expression of proteasome subunit &beta;5t in the human thymic cortex. Blood 113:5186-5191, 2009","DOI":"10.1182\/blood-2008-11-187633"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Nakagawa K, Matsuno Y, Kunitoh H, Maeshima A, Asamura H, <I>et al<\/I>.: Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 128:140-144, 2005","DOI":"10.1378\/chest.128.1.140"},{"key":"12","unstructured":"12 Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, <I>et al<\/I>.: Human proto-oncogene c-kit : a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6:3341-3351, 1987"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Nataili PG, Nicotra MR, Sures I, Santro E, Bigotti A, <I>et al<\/I>.: Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 52:6139-6143, 1992","DOI":"10.1002\/ijc.2910520207"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, <I>et al<\/I>.: Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 80:374-381, 1992","DOI":"10.1182\/blood.V80.2.374.374"},{"key":"15","unstructured":"15 Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, <I>et al<\/I>.: Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma\/dysgerminoma in human : immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 424:135-141, 1994"},{"key":"16","unstructured":"16 Matsuda R, Takahashi T, Nakamura S, Sekido Y, Nishida K, <I>et al<\/I>.: Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 142:339-346, 1993"},{"key":"17","unstructured":"17 Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M, <I>et al<\/I>.: CD117 : a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11:728-734, 1998"},{"key":"18","unstructured":"18 Cole SR, Aylett GW, Harvey NL, Cambareri AC, Ashman LK: Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia. Leukemia 10:288-296, 1996"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase activity : a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703, 2002","DOI":"10.1200\/JCO.20.6.1692"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Yoo J, Kim CH, Song SH, Shim BY, Jeong YJ, <I>et al<\/I>.: Expression of caspase-3 and c-myc in non-small cell lung cancer. Cancer Res Treat 36:303-307, 2004","DOI":"10.4143\/crt.2004.36.5.303"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Arber DA, Tamayo R, Weiss LM: Paraffin section detection of the c-kit gene product (CD117) in human tissues : value in the diagnosis of mast cell disorders. Hum Pathol 29:498-504, 1998","DOI":"10.1016\/S0046-8177(98)90066-1"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Pan CC, Chen PC, Chiang H: Kit (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 202:375-381, 2004","DOI":"10.1002\/path.1514"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Tarakhovsky A, Kanner SB, Hombach J, Ledbetter JA, M&uuml;ller W: A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science 269:535-537, 1995","DOI":"10.1126\/science.7542801"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Van de Velde H, von Hoegen I, Luo W, Parnes JR, Thielemans K: The B-cell surface protein CD72\/Lyb-2 is the ligand for CD5. Nature 351:662-665 1991","DOI":"10.1038\/351662a0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Luo W, Van de Velde H, von Hoegen I, Parnes JR, Thielemans K: Ly-1 (CD5), a membrane glycoprotein of mouse T lymphocytes and a subset of B cells, is a natural ligand of the B cell surface protein Lyb-2 (CD72). J Immunol 148:1630-1634, 1992","DOI":"10.4049\/jimmunol.148.6.1630"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Dorfman DM, Shahsafaei A, Chan JK: Thymic carcinomas, but not thymomas and carcinomas of other sites show CD5 immunoreactivity. Am J Surg Pathol 21:936-940, 1997","DOI":"10.1097\/00000478-199708000-00008"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Olson AL, Pessin JE: Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr 16:235-256, 1966","DOI":"10.1146\/annurev.nu.16.070196.001315"},{"key":"28","unstructured":"28 Clavo AC, Brown RS, Wahl RL: Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 36:1625-1632, 1995"},{"key":"29","unstructured":"29 Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J: Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 56:1164-1167, 1996"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Brown RS, Wahl RL: Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72:2979-2985, 1993","DOI":"10.1002\/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Mellanen P, Minn H, Gr&eacute;nman R, H&auml;rk&ouml;nen P: Expression of glucose transporters in head-and-neck tumors. Int J Cancer 56:622-629, 1994","DOI":"10.1002\/ijc.2910560503"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Nagase Y, Takata K, Moriyama N, Aso Y, Murakami T, <I>et al<\/I>.: Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol 153:798-801, 1995","DOI":"10.1016\/S0022-5347(01)67725-5"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT: Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80:1046-1051 1997","DOI":"10.1002\/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Rudlowski C, Moser M, Becker AJ, Rath W, Buttner R, <I>et al<\/I>.: GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology 66:404-410, 2004","DOI":"10.1159\/000079489"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, <I>et al<\/I>.: Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 20:215-220, 2007","DOI":"10.1038\/modpathol.3800732"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Turksen K, Troy TC: Barriers built on claudins. J Cell Sci 117:2435-2447, 2004","DOI":"10.1242\/jcs.01235"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Kr&auml;mer F, White K, Kubbies M, Swisshelm K, Weber BH: Gnenomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer. Hum Genet 107:249-256, 2000","DOI":"10.1007\/s004390000375"},{"key":"38","unstructured":"38 Tok&eacute;s AM, Kulka J, Paku S, Szik A, P&aacute;ska C, <I>et al<\/I>.: Claudin-1, -3, and -4 proteins and mRNA expression in benign and malignant breast lesions : a research study. Breast Cancer Res 7:R296-305, 2005"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE: Claudin-1 is a strong prognostic indicator in stage II colonic cancer : a tissue microarray study. Mod Pathol 18:511-518, 2005","DOI":"10.1038\/modpathol.3800301"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Kominsky SL, Argani P, Korz D, Evron E, Raman V, <I>et al<\/I>.: Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma <I>in situ<\/I> and invasive ductal carcinoma of the breast. Oncogene 22:2021-2033, 2003","DOI":"10.1038\/sj.onc.1206199"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Al Moustafa AE, Alaoui-Jamali MA, Batist G, Hernandez-Perez M, Serruya C, <I>et al<\/I>.: Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 21:2634-2640, 2002","DOI":"10.1038\/sj.onc.1205351"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Morin PJ: Claudin proteins in human cancer : promising new targets for diagnosis and therapy. Cancer Res 65:9603-9606, 2005","DOI":"10.1158\/0008-5472.CAN-05-2782"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Morita K, Tsukita S, Miyachi Y: Tight junction-associated proteins (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen's disease. Br J Dermatol 151:328-334, 2004","DOI":"10.1111\/j.1365-2133.2004.06029.x"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Yamada Y, Tamura U, Ishizu A, Kiuchi T, Marukawa K, <I>et al<\/I>.: Expression of proteasome subunit &beta;5t in thymic epithelial tumors. Am J Surg Pathol 35:1296-1304, 2011","DOI":"10.1097\/PAS.0b013e3182237f5d"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Burger PC, Shibata T, Kleihues P: The use of the monoclonal antibody Ki-67 in the identification of proliferating cells : application to surgical neuropathology. Am J Surg Pathol 10:611-617, 1986","DOI":"10.1097\/00000478-198609000-00003"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Montine TJ, Vandersteenhoven JJ, Aguzzi A, Boyko OB, Dodge RK, <I>et al<\/I>.: Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 34:674-678, 1994","DOI":"10.1227\/00006123-199404000-00016"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Lindboe CF, Torp SH: Comparison of Ki-67 equivalent antibody. J Clin Pathol 55:467-471, 2002","DOI":"10.1136\/jcp.55.6.467"},{"key":"48","unstructured":"48 B&aacute;rtek J, B&aacute;rtkov&aacute; J, Vojt&#277;sek B, Staskov&aacute; Z, Luk&aacute;s J, <I>et al<\/I>.: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699-1703, 1991"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 89:7491-7495, 1992","DOI":"10.1073\/pnas.89.16.7491"},{"key":"50","unstructured":"50 Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, <I>et al<\/I>.: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52:2340-2343, 1992"},{"key":"51","unstructured":"51 Jiang D, Srinivasan A, Lozano G, Robbins PD: SV40 T antigen abrogates p53-mediiated transcriptional activity. Onocogene 8:2805-2812, 1993"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Hino N, Kondo K, Miyoshi T, Uyama T, Monden Y: High frequency of p53 protein expression in thymic carcinoma but not in thymoma. Br J Cancer 76:1361-1366, 1997","DOI":"10.1038\/bjc.1997.561"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T14:01:14Z","timestamp":1688306474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/53\/1\/53_9\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.53.9","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}